Cardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Update

Cardiff Oncology, Inc. (NASDAQ:CRDF) was the recipient of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 8,180,000 shares, an increase of 6.0% from the November 15th total of 7,720,000 shares. Based on an average daily volume of 1,480,000 shares, the days-to-cover ratio is currently 5.5 days.

Cardiff Oncology Price Performance

Shares of NASDAQ:CRDF opened at $4.03 on Tuesday. The firm has a market capitalization of $206.05 million, a price-to-earnings ratio of -4.29 and a beta of 1.89. The business’s 50 day simple moving average is $2.92 and its 200-day simple moving average is $2.61. Cardiff Oncology has a 12 month low of $1.30 and a 12 month high of $6.42.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on CRDF shares. Piper Sandler raised their price target on Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a report on Friday. Craig Hallum assumed coverage on Cardiff Oncology in a report on Friday, September 6th. They issued a “buy” rating and a $8.00 target price for the company. Finally, HC Wainwright decreased their target price on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, November 8th.

Insider Buying and Selling

In other news, Director Gary W. Pace purchased 350,115 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average cost of $2.60 per share, with a total value of $910,299.00. Following the completion of the acquisition, the director now directly owns 1,047,876 shares of the company’s stock, valued at approximately $2,724,477.60. This trade represents a 50.18 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.80% of the company’s stock.

Institutional Trading of Cardiff Oncology

Institutional investors have recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its position in shares of Cardiff Oncology by 380.6% in the second quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock valued at $2,699,000 after buying an additional 962,940 shares in the last quarter. Blair William & Co. IL increased its holdings in Cardiff Oncology by 32.2% during the 2nd quarter. Blair William & Co. IL now owns 227,630 shares of the company’s stock valued at $505,000 after acquiring an additional 55,450 shares in the last quarter. Point72 DIFC Ltd acquired a new position in Cardiff Oncology during the second quarter worth about $27,000. GSA Capital Partners LLP lifted its holdings in shares of Cardiff Oncology by 432.7% in the third quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock valued at $498,000 after purchasing an additional 151,613 shares in the last quarter. Finally, Rhumbline Advisers acquired a new stake in shares of Cardiff Oncology in the second quarter valued at approximately $102,000. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.